On July 1, 2026, the U.S. Drug Enforcement Administration moved to place concentrated 7-hydroxymitragynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act — the same category reserved for heroin and LSD. It’s a significant escalation in how the federal government treats one of the most potent compounds associated with the kratom plant.
Why 7-OH Is Different From the Leaf
This movement targets concentrated and synthetic 7-OH — not natural leaf kratom. The distinction is pharmacological: 7-OH acts directly on the brain’s mu-opioid receptors, producing effects and risks similar to traditional opioids.
The Department of Health and Human Services and the FDA concluded that concentrated 7-OH has no accepted medical use and a high potential for abuse, addiction, and respiratory depression. That finding builds on the FDA’s 2025 recommendation to schedule the compound specifically because of its opioid-like properties.
What the Rule Actually Covers
The DEA published two Notices of Intent in the Federal Register on July 6, 2026. Here’s what falls under the proposed ban:
- Concentration threshold: Products containing 7-OH above 0.05% dry weight, or more than 1 mg per product.
- Synthetic derivatives: The related compounds MP, MGM-15, and MGM-16 are also covered.
- Scheduling level: Schedule I — placing these substances alongside heroin, LSD, and other drugs of abuse with no recognized medical use.
The Timeline
- The temporary ban can take effect around August 5, 2026, following a 30-day public comment period.
- Emergency scheduling lasts up to two years, and can be extended for one additional year.
Sources: U.S. Drug Enforcement Administration, “Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I,” Notice of Intent, 91 Fed. Reg. 40917 (July 6, 2026); Reuters, “DEA moves to place some strong kratom-related products under strict federal drug control,” July 1, 2026.